Netherlands· NL-20bb8fabea53
Ovitrelle 250 microgram oplossing voor injectie in voorgevulde pen
A choriogonadotropin alfa product containing choriogonadotropine alfa, registered in Netherlands by Merck Europe B.V.. The same ATC class is registered in 14 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Choriogonadotropin alfa is registered in 14 of 19 countries.
Countries holding a registration under ATC G03GA08 (choriogonadotropin alfa), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 9 of them publish a price we can compare per daily dose
Choriogonadotropin alfa · ATC G03GA08
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- CHORIOGONADOTROPINE ALFA
- Manufacturer
- Merck Europe B.V.
- Country
- Netherlands (NL)
- ATC code
- G03GA08
- ATC class
- Choriogonadotropin alfa
- Defined daily dose
- 0.25 mg, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/00/165
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Choriogonadotropin alfa in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- IrelandOvitrelle 250 micrograms solution for injection in pre-filled penMerck Europe B.V.
- FinlandOvitrelleMerck Europe B.V.
- NorwayOvitrelle2care4 ApS
- United KingdomOvitrelle 250microgram powder and solvent for solution for injection vialsMerck Serono Ltd
- IcelandOvitrelleMerck Europe B.V.*
- CanadaOVIDRELEMD SERONO, A DIVISION OF EMD INC., CANADA
- CzechiaOVITRELLEMerck Europe B.V., Amsterdam
- FranceOVITRELLE 250 microgrammes, solution injectable en stylo prérempliMERCK EUROPE (PAYS-BAS)
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ovitrelle
- Liechtenstein · Ovitrelle
- Norway · Ovitrelle
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dbacde9a-2285-49d2-a62a-2ceff91bae2b GET /v1/drugs/dbacde9a-2285-49d2-a62a-2ceff91bae2b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oplossing voor injectie",
"route": "Subcutaan gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/ovitrelle-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Choriogonadotropin Alfa",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp106710",
"excipients": [
"DINATRIUMWATERSTOFFOSFAAT 2-WATER (E 339)",
"FOSFORZUUR (E 338)",
"MANNITOL (D-) (E 421)",
"METHIONINE, (L-)",
"NATRIUMDIWATERSTOFFOSFAAT 1-WATER (E 339)",
"NATRIUMHYDROXIDE (E 524)",
"POLOXAMEER 188",
"WATER VOOR INJECTIE"
],
"substances": [
"CHORIOGONADOTROPINE ALFA"
],
"leaflet_url": null,
"authorised_at": "2011/06/23",
"procedure_number": "EMEA/H/C/000320",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/00/165",
"additional_monitoring": "N"
}See everything about choriogonadotropin alfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.